NEWS PROVIDED BY IO Biotech Jan 13, 2021, 02:00 ET COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ — IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare …
Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer
– Financing in Support of Company’s Goal of Developing Targeted Therapies to Improve the Lives of Women with Cancer – Lead Investor Vivo Capital is Joined by Additional New Investors Avoro Capital Advisors, Funds and Accounts Managed by BlackRock, Deerfield Management Company and OrbiMed, and All Existing Institutional Investors News provided by Olema Pharmaceuticals, Inc …
Gilead Sciences to Acquire Immunomedics
Gilead Sciences to Acquire Immunomedics — Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors — — Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and Best-in-Class Potential — — Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology …
PMV Pharma Closes $70 Million in Series D Financing
Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV Pharma August 03, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc. CRANBURY, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the completion …
Praxis Precision Medicines Announces $110 Million Financing
Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio July 28, 2020 08:59 AM Eastern Daylight Time CAMBRIDGE, Mass.–BUSINESS WIRE–Praxis Precision Medicines, Inc., a clinical-stage company translating genetic insights into the development of therapies for people with central nervous system disorders, today announced that it has raised approximately $110 million …
+1 212.937.4970